<a href="https://www.fiercebiotech.com/biotech/indivior-fails-phase-2-expects-significant-impact-rd-team" hreflang="en">Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2</a>
Indivior Pharmaceuticals has halted the internal development of its opioid use disorder drug INDV-2000 after it failed to meet primary endpoints in a phase 2 trial, which the company's CSO indicated will significantly impact the R&D team. Despite the setback, there were some encouraging results at a lower dose, and Indivior plans to seek a partner to explore these findings further while also dropping another drug, INDV-6001, from its pipeline.
For a professional interested in healthtech and biotech, the key takeaway from Indivior's recent developments is the potential partnership opportunity for the orexin-1 receptor antagonist drug. Despite the phase 2 trial missing its primary endpoint, the 200-mg dose showed a biologically coherent signal with higher abstinence rates, indicating that further exploration by a willing partner could be valuable. This represents a strategic opportunity for investment or collaboration in the substance use disorder space, leveraging the supportive clinical findings and orexin-1 mechanism.